$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000082787115000042 Filed on August 11, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$6.002M	$5.792M
YoY Change	3.63%	14.13%
Cost Of Revenue	$3.348M	$1.556M
YoY Change	115.17%	-46.8%
Gross Profit	$2.654M	$4.236M
YoY Change	-37.35%	97.02%
Gross Profit Margin	44.22%	73.14%
Selling, General & Admin	$5.111M	$2.673M
YoY Change	91.21%	113.66%
% of Gross Profit	192.58%	63.1%
Research & Development	$5.878M	$4.545M
YoY Change	29.33%	178.44%
% of Gross Profit	221.48%	107.29%
Depreciation & Amortization	$10.00K	$20.00K
YoY Change	-50.0%	-66.67%
% of Gross Profit	0.38%	0.47%
Operating Expenses	$14.34M	$8.774M
YoY Change	63.4%	129.97%
Operating Profit	-$8.335M	-$2.982M
YoY Change	179.51%	-336.71%
Interest Expense	$3.000K	$5.000K
YoY Change	-40.0%	-68.79%
% of Operating Profit
Other Income/Expense, Net	$5.000K	$48.00K
YoY Change	-89.58%	-109.5%
Pretax Income	-$8.330M	-$2.934M
YoY Change	183.91%	-488.83%
Income Tax	-$153.0K	$0.00
% Of Pretax Income
Net Earnings	-$8.177M	-$2.934M
YoY Change	178.7%	-488.83%
Net Earnings / Revenue	-136.24%	-50.66%
Basic Earnings Per Share	-$0.53	-$0.21
Diluted Earnings Per Share	-$0.53	-$0.21
COMMON SHARES
Basic Shares Outstanding	15.55M shares	14.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$103.7M	$49.80M
YoY Change	108.23%	361.11%
Cash & Equivalents	$13.69M	$49.79M
Short-Term Investments	$90.00M
Other Short-Term Assets	$198.0K	$408.8K
YoY Change	-51.56%	-89.52%
Inventory	$2.325M	$329.0K
Prepaid Expenses
Receivables	$12.98M	$6.712M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$120.6M	$57.76M
YoY Change	108.73%	277.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$374.0K	$359.5K
YoY Change	4.03%	-10.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$104.0K	$45.00K
YoY Change	131.11%
Total Long-Term Assets	$478.0K	$404.5K
YoY Change	18.17%	-19.1%
TOTAL ASSETS
Total Short-Term Assets	$120.6M	$57.76M
Total Long-Term Assets	$478.0K	$404.5K
Total Assets	$121.0M	$58.16M
YoY Change	108.1%	268.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.783M	$2.521M
YoY Change	89.76%	57.53%
Accrued Expenses	$13.54M	$7.469M
YoY Change	81.26%	397.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.58M	$16.25M
YoY Change	51.28%	20.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00
YoY Change		-100.0%
Total Long-Term Liabilities	$0.00	$0.00
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.58M	$16.25M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$24.60M	$16.20M
YoY Change	51.85%	14.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$98.16M	-$95.07M
YoY Change	3.25%
Common Stock	$15.00K	$14.02K
YoY Change	6.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$96.45M	$41.91M
YoY Change
Total Liabilities & Shareholders Equity	$121.0M	$58.16M
YoY Change	108.1%	268.1%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$8.177M	-$2.934M
YoY Change	178.7%	-488.83%
Depreciation, Depletion And Amortization	$10.00K	$20.00K
YoY Change	-50.0%	-66.67%
Cash From Operating Activities	-$12.12M	-$4.660M
YoY Change	160.09%	24.27%
INVESTING ACTIVITIES
Capital Expenditures	-$290.0K	-$10.00K
YoY Change	2800.0%	-66.67%
Acquisitions
YoY Change
Other Investing Activities	-$74.00M	$0.00
YoY Change
Cash From Investing Activities	-$74.29M	-$10.00K
YoY Change	742800.0%	-66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	170.0K	-420.0K
YoY Change	-140.48%	-104.27%
NET CHANGE
Cash From Operating Activities	-12.12M	-4.660M
Cash From Investing Activities	-74.29M	-10.00K
Cash From Financing Activities	170.0K	-420.0K
Net Change In Cash	-86.24M	-5.090M
YoY Change	1594.3%	-184.13%
FREE CASH FLOW
Cash From Operating Activities	-$12.12M	-$4.660M
Capital Expenditures	-$290.0K	-$10.00K
Free Cash Flow	-$11.83M	-$4.650M
YoY Change	154.41%	25.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	975899	shares
	us-gaap	Interest Expense InterestExpense	6000	USD
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15589844	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	EAGLE PHARMACEUTICALS, INC.
CY2014Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	839000	USD
CY2015Q2	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	1047000	USD
CY2014Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1307000	USD
CY2015Q2	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1139000	USD
	egrx	Deferred Ipo Costs DeferredIPOCosts	-1000	USD
	egrx	Deferred Ipo Costs DeferredIPOCosts	0	USD
	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	8000	USD
	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	78000	USD
	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	554000	USD
	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-81000	USD
CY2015Q1	egrx	Maximum Expected Cash Proceeds On Additional Milestones MaximumExpectedCashProceedsOnAdditionalMilestones	90000000	USD
CY2014Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	148000	USD
CY2015Q2	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	49000	USD
CY2014Q4	egrx	Prepaid Product Costs PrepaidProductCosts	1020000	USD
CY2015Q2	egrx	Prepaid Product Costs PrepaidProductCosts	424000	USD
	egrx	Royalty Revenue Commercial Partners Obligationof Sales Report Term RoyaltyRevenueCommercialPartnersObligationofSalesReportTerm	P60D
CY2014Q1	egrx	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	1788	shares
	egrx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1096000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3501000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4783000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11956000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12982000	USD
CY2014Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	0	USD
CY2014Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	0	USD
CY2015Q2	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	282000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12165000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13538000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	502000	USD
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	678000	USD
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1025000	USD
CY2015Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1120000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137577000	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	194596000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1593000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	164000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	304000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1209000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1593000	USD
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	994479	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2699334	shares
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1836327	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1556815	shares
CY2014Q4	us-gaap	Assets Assets	50094000	USD
CY2015Q2	us-gaap	Assets Assets	121029000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	49707000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	120551000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9974000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49791000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34869000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13686000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	39817000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-21183000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2035598	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14036680	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15589844	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14036680	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15589844	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	14000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	1556000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4915000	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	3348000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	9296000	USD
CY2014Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	0	USD
CY2015Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	429000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6520000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6260000	USD
	us-gaap	Depreciation Depreciation	51000	USD
	us-gaap	Depreciation Depreciation	22000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	383000	USD
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-273000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2934000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6914000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8330000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11766000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1295000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-153000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	246000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	174000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1282000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	120000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1026000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2731000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1373000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3760000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-260000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	329000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1083000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	59000	USD
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2014Q2	us-gaap	Interest Expense InterestExpense	5000	USD
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Interest Paid InterestPaid	6000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	3000	USD
	us-gaap	Interest Expense InterestExpense	4000	USD
	us-gaap	Interest Paid InterestPaid	4000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1242000	USD
CY2015Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	452000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	1242000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	2325000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	USD
CY2015Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	591000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1282000	USD
CY2015Q2	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	1873000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	1100000	USD
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	25000	USD
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	15000	USD
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	68000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	140000	USD
CY2015Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	95000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	163000	USD
CY2014Q4	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	0	USD
CY2015Q2	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	392000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50094000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	121029000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22186000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	24581000	USD
CY2014Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	596000	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	665000	USD
CY2015Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1612000	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2571000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46587000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55427000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-90326000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6738000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13716000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-2934000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5619000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-8177000	USD
	us-gaap	Net Income Loss NetIncomeLoss	11520000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2934000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6153000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8177000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2934000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1096000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6153000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8177000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	11520000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	48000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-328000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	8774000	USD
	us-gaap	Operating Expenses OperatingExpenses	17382000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	14337000	USD
	us-gaap	Operating Expenses OperatingExpenses	30556000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2982000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6586000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8335000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	11755000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	304000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	273000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	289000	USD
CY2015Q2	us-gaap	Other Assets Current OtherAssetsCurrent	198000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104000	USD
CY2014Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	35000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	36000	USD
CY2015Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2014Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	3500000	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	3765000	USD
CY2015Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	30000000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	187000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	327000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	89999000	USD
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1640000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1559000	USD
CY2014Q4	us-gaap	Prepaid Insurance PrepaidInsurance	183000	USD
CY2015Q2	us-gaap	Prepaid Insurance PrepaidInsurance	496000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	46069000	USD
CY2015Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	30000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	21000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	21000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	342000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	374000	USD
CY2015Q2	us-gaap	Purchase Obligation PurchaseObligation	8505000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4545000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8339000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5878000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12163000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109683000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98163000	USD
CY2014Q2	us-gaap	Royalty Revenue RoyaltyRevenue	1942000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	5506000	USD
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	2272000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	5525000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	350000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1525000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3730000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6786000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	5792000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	10796000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	6002000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	42311000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2673000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4128000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5111000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9097000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	304000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1593000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5684
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.558
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3011
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3033
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0216
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0221
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0209
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0209
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0211
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0169
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0142
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0142
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments	89999000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	27908000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	96448000	USD
CY2014Q2	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	534000	USD
CY2015Q2	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	14020133	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	11455408	shares
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15546796	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15876397	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14020133	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11455408	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15546796	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14900498	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2015</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and related notes included in our annual report on Form 10-K for the fiscal year ended September 30, 2014, filed with the Securities and Exchange Commission on December 22, 2014.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 20, 2015, the Board of Directors of the Company authorized a change in the Company’s fiscal year end from September 30</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;"> to December 31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">.  The change was intended to better align the Company’s fiscal year with the business cycles of other specialty pharmaceutical companies. As a result of the change in fiscal year, the Company’s 2015 fiscal year began on January 1, 2015 and will end on December 31, 2015.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the change in fiscal year, on February 17, 2015 the Company filed a Transition Report on Form 10-Q covering the transition period from October 1, 2014 to December 31, 2014.</font></div></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000827871-15-000042-index-headers.html	Edgar Link	pending
0000827871-15-000042-index.html	Edgar Link	pending
0000827871-15-000042.txt	Edgar Link	pending
0000827871-15-000042-xbrl.zip	Edgar Link	pending
egrx-20150630.xml	Edgar Link	completed
egrx-20150630.xsd	Edgar Link	pending
egrx-20150630_cal.xml	Edgar Link	unprocessable
egrx-20150630_def.xml	Edgar Link	unprocessable
egrx-20150630_lab.xml	Edgar Link	unprocessable
egrx-20150630_pre.xml	Edgar Link	unprocessable
egrx_q2x2015.htm	Edgar Link	pending
exhibit311q22015.htm	Edgar Link	pending
exhibit312q22015.htm	Edgar Link	pending
exhibit321q22015.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2015 Q2 Form 10-Q Financial Statement

#000082787115000042 Filed on August 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2015 Q2 Form 10-Q Financial Statement

#000082787115000042 Filed on August 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx